Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies
- PMID: 10493889
- DOI: 10.1006/exmp.1999.2266
Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies
Abstract
We have studied two anti-p185 antibodies: the monoclonal antibody 7. 16.4 and rhuMAb 4D5, which were raised against the the ectodomain of rat (p185(neu)), and the human (p185(her2/neu)) homolog, respectively. Studies on the structure of these two antibodies indicate that they share structural similarity in the variable region, especially the CDR3 region, which determines the antibody-antigen interaction. Further studies by flow cytometry revealed that 7.16.4 can compete with rhuMAb4D5 for binding to the cell surface p185(her2/neu), suggesting that these two antibodies share an epitope on the p185 receptor. Furthermore, 7.16.4 can also inhibit proliferation and transformation caused by p185(her2/neu). Moreover the rhuMAb 4D5 binds to the rat p185(neu). With the observation that 7.16.4 positively stains human breast cancer tissues that overexpress p185(her2/neu), 7.16.4 may be useful for the pathological diagnosis and therapy of human tumors.
Copyright 1999 Academic Press.
Similar articles
-
AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185her2/neu.Oncogene. 2006 Dec 14;25(59):7740-6. doi: 10.1038/sj.onc.1209745. Epub 2006 Jun 19. Oncogene. 2006. PMID: 16785990
-
Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes.Oncogene. 2008 Jun 19;27(27):3870-4. doi: 10.1038/onc.2008.13. Epub 2008 Feb 11. Oncogene. 2008. PMID: 18264138 Free PMC article.
-
Structural insights into the down-regulation of overexpressed p185(her2/neu) protein of transformed cells by the antibody chA21.J Biol Chem. 2011 Sep 9;286(36):31676-83. doi: 10.1074/jbc.M111.235184. Epub 2011 Jun 16. J Biol Chem. 2011. PMID: 21680730 Free PMC article.
-
Treatment of meningeal breast cancer xenografts in the rat using an anti-p185/HER2 antibody.Clin Cancer Res. 2001 Jul;7(7):2050-6. Clin Cancer Res. 2001. PMID: 11448923
-
C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment.Clin Chim Acta. 2002 Aug;322(1-2):11-9. doi: 10.1016/s0009-8981(02)00134-1. Clin Chim Acta. 2002. PMID: 12104076 Review.
Cited by
-
Structure based antibody-like peptidomimetics.Pharmaceuticals (Basel). 2012 Feb 16;5(2):209-35. doi: 10.3390/ph5020209. Pharmaceuticals (Basel). 2012. PMID: 24288089 Free PMC article.
-
Neuregulin-ErbB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury.J Neurosci. 2010 Apr 14;30(15):5437-50. doi: 10.1523/JNEUROSCI.5169-09.2010. J Neurosci. 2010. PMID: 20392965 Free PMC article.
-
IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer.Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2201376119. doi: 10.1073/pnas.2201376119. Epub 2022 Jul 25. Proc Natl Acad Sci U S A. 2022. PMID: 35878022 Free PMC article.
-
Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors.Cell Rep. 2015 Sep 29;12(12):2049-59. doi: 10.1016/j.celrep.2015.08.044. Epub 2015 Sep 10. Cell Rep. 2015. PMID: 26365188 Free PMC article.
-
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.Cancer Res. 2017 Oct 1;77(19):5374-5383. doi: 10.1158/0008-5472.CAN-16-2774. Epub 2017 Aug 17. Cancer Res. 2017. PMID: 28819024 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous